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Background: We conducted a systematic literature review and meta-analysis of observational studies investigating
adherence to the 2007 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) lifestyle
recommendations for cancer prevention and health outcomes.
Patients and methods: We searched PubMed and the in-house database of the WCRF Continuous Update Project for
publications up to June 2019. Cross-sectional studies were only narratively reviewed given their heterogeneity while
ﬁndings of cohort/case-control studies were synthesized in umbrella reviews and meta-analyses. Summary relative
risks (RRs) and 95% conﬁdence intervals (CI) were estimated using a random-effects model when at least two
studies reported results on a speciﬁc outcome.
Results: Thirty-eight articles (17 prospective, 8 case-control, and 13 cross-sectional studies) were included. The summary
RR per each point increment in the 2007 WCRF/AICR score was 0.90 (95% CI: 0.87e0.93, n ¼ 11) for breast cancer,
regardless of hormone receptor and menopausal status, 0.86 (95% CI: 0.82e0.89, n ¼ 10) for colorectal cancer, and
0.93 (95% CI: 0.89e0.96, n ¼ 2) for lung cancer risk. No statistically signiﬁcant associations were reported for prostate
(n ¼ 6) and pancreatic cancers (n ¼ 2). Adherence to the recommendations was associated with lower overall
mortality (RR ¼ 0.90, 95% CI 0.84e0.96, n ¼ 3) and cancer-speciﬁc mortality (RR ¼ 0.91, 95% CI 0.89e0.92; n ¼ 3) in
healthy populations, as well as with higher survival in cancer patients (n ¼ 2). In cross-sectional studies, a healthier
plasma marker proﬁle and lower cancer risk factors in the general population and a better health status and quality of
life in cancer patients/survivors were reported.
Conclusions: Adhering to the 2007 WCRF/AICR recommendations is associated with lower risks of cancer incidence,
namely breast and colorectal cancers, and mortality. Primary prevention of cancer should emphasize modiﬁcation of
multiple lifestyle factors. Upcoming studies examining the recently updated 2018 guidelines will further clarify such
associations.
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Cancer prevalence is predicted to increase to over 29.5
million globally by 2040, with estimates showing that be-
tween 30% and 50% of the most common cancers might be
preventable through diet, nutrition, and physical activity.1,2
The combination of these factors in lifestyle patterns may
inﬂuence cancer risk more than each factor in isolation. For
this reason, evidence underpinning the association between
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352 https://doi.org/10.1016/j.annonc.2020.01.001reviewed in order to provide a robust understanding of the
epidemiology of cancer as a sound basis for research, public
education, and public policy.
In 2007, the World Cancer Research Fund/American
Institute for Cancer Research (WCRF/AICR) issued ten rec-
ommendations for cancer prevention based on the most
comprehensive collection of scientiﬁc evidence available at
that time.3 Taken together, the recommendations aim to
help people reduce their risk of cancer by having a healthy
weight, being physically active throughout life, and having
healthy patterns of diet and alcohol consumption (Box 1).
In 2012, a score reﬂecting combined adherence to such
guidelines (hereafter, the 2007 WCRF/AICR score) was
constructed in a large prospective study conducted in ten
European countries. This study found that higher adherence
to such recommendations was inversely associated withVolume 31 - Issue 3 - 2020
Box 1. WCRF/AICR 2007 recommendations for cancer prevention3
General recommendations
1. Body fatness e Be as lean as possible within the
normal range of body weight
2. Physical activity e Be physically active as part of
everyday life
3. Foods and drinks that promote weight gain e Limit
consumption of energy-dense foods and avoid sug-
ary drinks
4. Plant foods e Eat mostly foods of plant origin
5. Animal foods e Limit intake of red meat and avoid
processed meat
6. Alcoholic drinks e Limit alcoholic drinks
7. Preservation, processing, and preparation e Limit
consumption of salt and avoid moldy cereals (grains)
or pulses (legumes)
8. Dietary supplements e Aim to meet nutritional
needs through diet alone
Special recommendations
9. Breastfeeding e Mothers to breastfeed; children to
be breastfed
10. Cancer survivors e Follow the recommendations for
cancer prevention
M. Solans et al. Annals of Oncologycancer risk.4 Since then, numerous researchers have con-
structed similar scores in different settings and have studied
their association with different health outcomes, mostly
cancer incidence, but also mortality, cancer risk factors,
plasma biomarkers, and health status and quality of life in
cancer patients or survivors.
More evidence has accumulated since the publication of
the WCRF/AICR Second Expert Report and the cancer pre-
vention recommendations have been updated in the 2018
WCRF/AICR Third Expert Report.5 The revised recommen-
dations remain highly consistent with the previous report
but further emphasize the importance of adopting an overall
healthy lifestyle pattern for cancer prevention rather than
focusing on individual factors. Following that publication, a
collaborative group was formed to develop a standardized
scoring system and provide guidance for its applications.6
The analysis of previous ﬁndings, methodological chal-
lenges, and evidence gaps in the studies that implemented
scores based on the 2007 WCRF/AICR recommendations will
help to clarify future directions for upcoming studies.
Therefore, the aim of our study is to systematically review
and carry out a meta-analysis of the published literature
reporting associations between adherence to the 2007
WCRF/AICR recommendations and health outcomes.
METHODS
Literature search
Two reviewers (MS and DR) searched PubMed and two
reviewers (DC and TN) searched the in-house database of
the WCRF Continuous Update Project (CUP) (http://www.
wcrf.org/int/research-we-fund/continuous-update-project-Volume 31 - Issue 3 - 2020cup) for observational studies on the 2007 WCRF/AICR
score and health outcomes up to 5 June 2019. The
PubMed search strategy contained the following words:
‘World Cancer Research Fund’ or ‘WCRF’ or ‘American
Institute for Cancer Research’ or ‘AICR’ combined with
‘cancer’, ‘neoplasm’, ‘mortality’, or ‘health’. The CUP search
can be accessed online in the protocols for each cancer
through https://www.wcrf.org/dietandcancer/cancers. We
did not impose any language restriction in the search nor
contact any author for additional information.
Study selection
The inclusion criteria for the studies were (i) cohort, case-
control, and cross-sectional studies without restriction of
study population; (ii) studies that investigated the associa-
tions between adherence to a 2007 WCRF/AICR score and
any health outcome, and (iii) studies reporting estimates of
relative risk (RR) [e.g. hazard ratio (HR), risk ratio, or odds
ratio] with the corresponding measure of variability [95%
conﬁdence intervals (CI) or P value]. Studies using the 2007
WCRF/AICR score but only including dietary recommenda-
tions were not selected7e10 given that a strength and
novelty of the score is that it models an overall lifestyle
pattern including diet together with physical activity and
weight management. In addition, we excluded a birth
cohort in which the score was measured at mid-pregnancy
and micronucleus frequency (a biomarker of early genetic
effects) in mothers and newborns at birth.11
Data extraction
Study characteristics, operationalization of the 2007 WCRF/
AICR score, and study results were extracted by two re-
viewers (DR and MS) including the name of the ﬁrst author,
publication year, country or region, study design, sample
size and number of cases and deaths, gender, age, type of
outcome, WCRF/AICR score categories, RR estimates and
their corresponding 95% CI or P values, and confounder
adjustments used in the studies. The data on cancer out-
comes were extracted from the CUP database.
Displaying of ﬁndings
The results of all cohort and case-control studies were
included in an umbrella review that encompassed all
the relevant health outcomes identiﬁed. Categorical and
dose-response results were further summarized by health
outcome when at least two studies reported results and the
required information for conducting a meta-analysis. Cross-
sectional studies were only narratively reviewed given the
heterogeneity of the study designs and outcomes exam-
ined. For all sections, only results with the most compre-
hensive adjustment for confounders were considered.
Statistical analyses
We calculated the summary RRs and 95% CIs using random-
effects models that account for possible heterogeneity be-
tween studies.12 Both categorical (comparing the highesthttps://doi.org/10.1016/j.annonc.2020.01.001 353
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(per unit increment in the score) meta-analyses were
performed.
For the dose-response meta-analyses, we calculated the
RR estimates in the studies that reported results for a
different increment (e.g. per 0.5-point increase or 1-point
decrease) or from the categorical data using generalized
least-squares for trend estimation13 before pooling these
with other studies that reported results per 1 point increase.
To estimate dose-response trends from categorical data,
at least three levels of exposure, number of cases and non-
cases or population at risk, and exposure values per cate-
gory had to be available or estimated using standard
methods.14,15 All studies reported close-ended categories
(starting from 0 points), apart from one16 in which we
assumed 0 as the lowest boundary.
The Cochran Q test and I2 test statistic were used to assess
heterogeneity between studies.17 I2 <30%, 30% to <50%,
and 50% were considered low, moderate, and high pro-
portions of heterogeneity, respectively. Sources of hetero-
geneity were explored in subgroups deﬁned by study design
and geographical region. We also stratiﬁed results by
menopausal status and hormone receptor status for breast
cancer risk and by site for colorectal cancer. Small-study bias
such as publication bias was assessed by Egger’s test and
visual inspection of the funnel plots.18 Each study was
omitted in turn to examine its inﬂuence on the summary RR.
A two-tailed P value of <0.05 was considered as statis-
tically signiﬁcant in the analyses, except for the generally
low-powered Egger’s test, where a P value of <0.10 was
used as the cut-off point. All analyses were conducted using
Stata version 14.0 (StataCorp, College Station, TX).RESULTS
A total of 339 publications were identiﬁed. Of these, 272
were excluded on the basis of title and abstract, and 67 full-
text publications were retrieved and assessed for inclusion.
Twenty-nine publications were excluded for not fulﬁlling
the inclusion criteria (8 publications based on the 1997
WCRF/AICR recommendations, 14 descriptive studies, 4
publications only operationalizing dietary recommenda-
tions, 1 birth cohort, 1 overlapping study, and 1 review).
Hence, 38 publications were ﬁnally included in the sys-
tematic review: 13 cross-sectional studies,19e31 17 cohort
studies,4,32e47 and 8 case-control studies.16,48e54 Twenty
cohort and case-control studies assessed cancer inci-
dence,4,16,32e34,40e54 which, with the exception of one
study that did not provide enough information for dose-
response estimates,49 were all included in the cancer
incidence umbrella review. Among them 11 publications
on breast cancer,4,32,40e46,50,53 10 on colorectal cancer,
4,16,32e34,40,41,47,53,54 6 on prostate cancer,4,32,40,41,48,53 and
2 of each on lung4,41 and pancreatic4,51 cancers were
included in their respective meta-analyses. Finally, ﬁve
cohort studies assessed overall mortality, two studied cancer
survivors38,39 and three studied the general population,35e37
which were included in the mortality umbrella review.354 https://doi.org/10.1016/j.annonc.2020.01.001Those conducted on the general population were also
included in meta-analyses of all-cause,35,37 cancer,35e37 and
cardiovascular disease35,37 mortality (see supplementary
Flow Chart, available at Annals of Oncology online).
In all selected studies, adherence to or concordance with
the 2007 WCRF/AICR recommendations was operational-
ized based on the available data in the studies and the in-
dividual cut-off points indicated in the recommendations
(or the population distribution of the data). No standard
scoring approach had been previously developed and thus,
each study used different versions of the score that varied
considerably both in the number of recommendations
included (Table 1) and the cut-off points used in their
operationalization (supplementary Table S1, available at
Annals of Oncology online).
Most of the publications reported the distribution of soci-
odemographic characteristics according to the level of
adherence to the 2007 WCRF/AICR score in their study pop-
ulations. The largest study, the European Prospective Investi-
gation into Cancer and Nutrition (EPIC) cohort that included
over half a million European participants, observed that
those with higher scores tended to be younger, more highly
educated, and less likely to be smokers or suffer from
chronic diseases (e.g. hyperlipidemia, hypertension).4,35
These patterns were also seen in populations of cancer sur-
vivors, in which higher scores were reported in those in-
dividuals with high educational level, non-smokers, fewer
comorbid conditions, and greater perceived health status.38,39
Association with cancer risk
A total of 12 cohort and 8 case-control studies explored the
association between the WCRF/AICR score and cancer risk
(Table 2). Breast and colorectal cancers were the cancer
sites most often investigated.
Breast cancer. Nine cohort4,32,40e46 and three case-control
studies49,50,53 assessed adherence to the WCRF/AICR rec-
ommendations and risk of breast cancer (Table 2). In linear
dose-response meta-analysis, including 21 753 breast can-
cer cases in 11 studies,4,32,40e46,50,53 each one-point incre-
ment in the 2007 WCRF/AICR score resulted in a 10% (95%
CI, 13% to 6%) lower risk of breast cancer (Figure 1). Sub-
stantial heterogeneity across the studies was detected
(I2 69.8%; P for heterogeneity <0.001), which is partly
explained by differences in study design [i.e. case-control
studies tend to observe stronger associations (Figure 1)],
and study size [i.e. there was evidence of small-study effect/
publication bias according to the funnel plot (data not
shown)]. Results were similar in the meta-analysis stratiﬁed
by geographical location, menopausal status, and hormone
receptor tumor subtype (Table 3). Inﬂuence analyses did
not suggest a strong inﬂuence from any of the individual
studies on the summary estimates (data not shown).
The highest versus lowest meta-analysis, including 11
studies4,40e43,45,47,49,50,53 and 22 609 cases, yielded
consistent results overall (RRhighestvslowest ¼ 0.74, 95% CI
0.65e0.83, I2 ¼ 67.6%, P for heterogeneity <0.001) and by
subgroups (Table 3).Volume 31 - Issue 3 - 2020
Table 1. Recommendations included in the 2007 WCRF/AICR score
Author, year BW PA FPWG PF AF A S SU BF CS Other Range
Cohort studies
Romaguera, 2012 Y Y Y Y Y Y Y 0e7 (0e6 _)
Vergnaud, 2013 Y Y Y Y Y Y Y 0e7 (0e6 _)
Hastert, 2013 Y Y Y Y Y Y 0e6
Inoue-Choi, 2013 Y Y Y Y Y Y Y 0e7
Catsburg, 2014 Y Y Y Y Y Y Y 0e7
Hastert, 2014 Y Y Y Y Y Y 0e6
Makarem, 2015 Y Y Y Y Y Y Y 0e7
Romaguera, 2015 Y Y Y Y Y Y Y 0e7 (0e6 _)
Nomura, 2016 (IWHS) Y Y Y Y Y Y Y 0e8
Harris, 2016 Y Y Y Y Y Y Y 0e7
Nomura, 2016 (BWHS, BC) Y Y Y Y Y Y Y 0e7
Nomura, 2016 (BWHS, CRC) Y Y Y Y Y Y Y 0e7
Lohse, 2016 Y Y Y Y Y Y Y 0e9
Hastert, 2016 Y Y Y Y Y Y 0e6
Jones, 2018 Y Y Y Y Y Y Y Y 0e8
Lavalette, 2018 Y Y Y Y Y Y Y Y 0e8
Xu, 2019 Y Y Y Y Y Y 0e6
Case-control studies
Er, 2014 Y Y Y Y Y Y 0e6
Castelló, 2015 Y Y Y Y Y Y Y Y Y 0e9 (0e8 _)
Fanidi, 2015 Y Y Y Y Y Y Y 0e7
Lucas, 2016 Y Y Y Y Y Y Y 0e7
Romaguera, 2017 Y Y Y Y Y Y 0e6
Turati, 2017 Y Y Y Y Y Y Y 0e7
Bravi, 2017 Y Y Y Y Y Y Y 0e7
El Kinany, 2019 Y Y Y Y Y Y 0e6
Cross-sectional studies
Inoue-Choi, 2013 Y Y Y Y Y Y 0e7
Arab, 2013 Y Y Y Y Y Y Y 0e9
Smith, 2014 Y Y Y Y Y Y 0e7
Morimoto, 2015 Y Y Y Y Y Y Y Y (Smoking) 0e8
Castelló, 2015 Y Y Y Y Y Y Y Y 0e8
Song, 2015 Y Y Y Y Y Y 0e12
Realdon, 2016 Y Y Y Y Y 0e6
Bruno, 2016 Y Y Y Y Y 0e5
Tabung, 2016 Y Y Y Y Y Y 0e6
Lei, 2018 Y Y Y Y Y Y 0e6
Breedveld-Peters, 2018 Y Y Y Y Y Y Y 0e10
Malcomson, 2018 Y Y Y Y Y Y Y Y (Smoking) 0e8
Van Veen, 2019 Y Y Y Y Y Y Y Y 0e8
A, alcohol; AF, animal foods; BF, breastfeeding; BW, body weight; CS, cancer survivors; FPWG, foods that promote weight gain; PA, physical activity; PF, plant foods; S, salt;
SU, dietary supplements; Y, yes.
M. Solans et al. Annals of OncologyColorectal cancer. Ten studies (six cohort4,32e34,40,41,47 and
three case-control studies16,53,54) evaluated adherence to
the 2007 WCRF/AICR recommendations and colorectal
cancer (Table 2). In the dose-response meta-analyses of all
studies, including 11 017 cases, each point increment in
the WCRF/AICR score resulted in a 14% (95% CI, 18% to
11%) lower risk of colorectal cancer (Figure 2). Heteroge-
neity across the studies was detected (I2 53.2%; P for
heterogeneity ¼ 0.02) and is mainly explained by differ-
ences in study design (Figure 2). Indeed, case-control
studies tend to ﬁnd stronger inverse associations, while
summary estimates from prospective studies are far more
consistent (I2 0.0%, P for heterogeneity ¼ 0.97). Further
sources of heterogeneity were explored in a meta-analysis
stratiﬁed by geographical location and site, which showed
similar associations across subgroups (Table 3). Overall,
there was no evidence of small-study bias/publication bias
and the inﬂuence analysis did not suggest a strong inﬂuence
from any of the individual studies on the summary esti-
mates (data not shown). The highest versus lowest meta-Volume 31 - Issue 3 - 2020analysis, based on nine studies4,16,33,34,40,41,47,53,54 and 10
954 cases, yielded similar results [RRhighestvslowest ¼ 0.62,
95% CI 0.56e0.70, I2 ¼ 49.7%, P for heterogeneity ¼ 0.04)]
(Table 3).
Other cancers. An umbrella review was conducted to
display the dose-response results of other studies evalu-
ating adherence to the 2007 WCRF/AICR recommendations
and cancer risk (Figure 3). A total of 19 studies including
data on 14 different cancer sites were displayed. For several
cancer sites (i.e. bladder, endometrial, kidney, liver, lung,
esophageal, ovarian, stomach, and upper aerodigestive
cancer), data came from a single cohort study, the EPIC
study. Dose-response meta-analyses revealed no associa-
tions for prostate (RR 0.99, 95% CI 0.97e1.02, I2 0.0%, P for
heterogeneity ¼ 0.43, n ¼ 6, 7444 cases) and pancreatic
(RR 0.86, 95% CI 0.62e1.18, I2 90.1%, P for heterogeneity
<0.001, n ¼ 2, 1082 cases) cancers. There was an inverse
association for lung cancer (RR 0.93, 95% CI 0.89e0.96,
I2 0.0%, P for heterogeneity ¼ 0.43, n ¼ 2, 2648 cases).https://doi.org/10.1016/j.annonc.2020.01.001 355
Table 2. Summary of studies
Author, year
Country
Study name
Study design
Sex, age (years)
Cases/total N
(years follow-up)
or cases/controls
Cases of secondary
outcomes
Outcome
Secondary
outcomes
Components of the
WCRF/AICR score
Score range
Comparison RR (95% CI)
RR (95% CI) for
secondary outcomes
Adjustment factors
A. Cancer incidence
Multiple cancer sites
Romaguera, 2012
Denmark, France,
Germany, Greece,
Italy, the Netherlands,
Spain, Sweden, UK
EPIC
Cohort
M/W (25e70 y)
36 994/386 355
(11 y)
(a) 9358
(b) 1148
(c) 906
(d) 4039
(e) 3880
(f) 2462
(g) 1514
(h) 783
(i) 745
(j) 696
(k) 602
(l) 522
(m) 312
Total cancer
(a) Breast
(b) Endometrial
(c) Ovarian
(d) Prostate
(e) Colorectal
(f) Lung
(g) Bladder
(h) Pancreas
(i) Kidney
(j) Stomach
(k) UADT
(l) Liver
(m) Esophageal
7 recommendations
(BW, PA, FPWG, PF,
AF, A, BF)
0e7 points women
0e6 points men
High (5e6 M/6e7 W)
versus Low (0e2
M/0e3 W)
For speciﬁc cancers, High
(4e6 M/5e7 W) versus
Low (0e2 M/0e3 W)
1-unit increase
0.82 (0.75e0.90)
(a) 0.84 (0.78e0.90)
(b) 0.77 (0.62e0.94)
(c) 0.99 (0.79e1.25)
(d) 1.02 (0.91e1.14)
(e) 0.73 (0.65e0.81)
(f) 0.86 (0.74e1.00)
(g) 0.84 (0.69e1.02)
(h)1.00 (0.78e1.28)
(i) 0.71 (0.54e0.93)
(j) 0.62 (0.46e0.83)
(k) 0.69 (0.50e0.95)
(l) 0.85 (0.62e1.16)
(m) 0.58 (0.38e0.90)
0.95 (0.93e0.97)
(a) 0.95 (0.93e0.97)
(b) 0.88 (0.83e0.94)
(c) 0.95 (0.89e1.02)
(d) 1.00 (0.96e1.04)
(e) 0.88 (0.84e0.91)
(f) 0.92 (0.89e0.96)
(g) 0.94 (0.89e1.00)
(h) 1.00 (0.92e1.08)
(i) 0.91 (0.85e0.99)
(j) 0.84 (0.78e0.91)
(k) 0.82 (0.74e0.90)
(l) 0.90 (0.81e0.99)
(m) 0.84 (0.73e0.96)
Center, age, sex, energy
intake, education, smoking,
chronic disease at baseline.
For women also contraceptive
pill use, hormone replacement
therapy use, age ﬁrst menarche,
age ﬁrst pregnancy,
menopausal status
Makarem, 2015
USA
Framingham
offspring cohort
Cohort
M/W (66 y)
480/2983
(11.5 y)
(a) 124
(b) 153
(c) 63
Obesity-related
cancers
(a) Breast
(b) Prostate
(c) Colorectal
7 recommendations
(BW, PA, FPWG, PF,
AF, A, S)
0e7 points
1-unit increase 0.94 (0.86e1.02)
(a) 0.87 (0.74e1.03)
(b) 1.08 (0.92e1.27)
(c) 0.87 (0.68e1.12)
Age, sex, smoking
Romaguera, 2017
Spain
Multi-case-control
Spain (MCC-Spain)
study
Case control
M/W (20e85 y)
3925/3431
(a) 1718
(b) 1169
(c) 533
(d) 1343
(e) 483
(f) 860
(g) 902
(h) 231
(i) 94
(j) 864
Colorectal, breast,
and prostate cancer
(a) Colorectal
(b) Colon
(c) Rectal
(d) Breast
(e) Premenopausal
(f) Postmenopausal
(g) HR+
(h) HER2+
(i) TN
(j) Prostate
6 recommendations
(BW, PA, FPWG, PF,
AF, A)
0e6 points
T3 (4.25e6 M/4.5e6 W)
versus T1 (0.25e3
M/0.5e3.5 W)
(a) 0.54 (0.45e0.63)
(b) 0.52 (0.43e0.63)
(c) 0.54 (0.41e0.71)
(d) 0.76 (0.63e0.92)
(e) 0.97 (0.68e1.40)
(f) 0.64 (0.51e0.81)
(g) 0.81 (0.65e1.00)
(h) 0.53 (0.36e0.78)
(i) 0.89 (0.51e1.54)
(j) 0.93 (0.72e1.20)
(k) 0.73 (0.52e1.01)
(l) 1.27 (0.92e1.76)
Sex, age, education, region,
family history of cancer (colorectal,
breast, or prostate, depending on
the analysis), smoking, and energy
intake. For breast cancer, also
hormone replacement therapy use,
oral contraceptive use, age at
menarche, age ﬁrst pregnancy,
number of children,
menopausal status
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Table 2. Continued
Author, year
Country
Study name
Study design
Sex, age (years)
Cases/total N
(years follow-up)
or cases/controls
Cases of secondary
outcomes
Outcome
Secondary
outcomes
Components of the
WCRF/AICR score
Score range
Comparison RR (95% CI)
RR (95% CI) for
secondary outcomes
Adjustment factors
(k) 445
(l) 405
(k) Prostate
undifferentiated
(l) Prostate
moderately/well
differentiated
1-unit increase (a) 0.75 (0.70e0.81)
(b) 0.75 (0.69e0.81)
(c) 0.76 (0.68e0.84)
(d) 0.85 (0.78e0.93)
(e) 0.99 (0.84e1.16)
(f) 0.78 (0.70e0.87)
(g) 0.87 (0.79e0.96)
(h) 0.79 (0.67e0.94)
(i) 0.87 (0.68e1.12)
(j) 0.98 (0.88e1.08)
(k) 0.87 (0.76e0.99)
(l) 1.13 (0.99e1.29)
Lavalette, 2018
France
NutriNet-Santé Study
Cohort
M/W (61.6 y)
1489/40 054
(2009e2017)
(a) 488
(b) 222
(c) 118
Total cancer
(a) Breast
(b) Prostate
(c) Colorectal
8 recommendations
(BW, PA, FPWG, PF, AF,
A, S, SU)
0e8 points
Q5 (5.75e8 M/6e8 W)
versus Q1 (0.75e3.5 M/
0.75e3.75 W)
1-unit increase
0.66 (0.55e0.79)
(a) 0.64 (0.46e0.89)
(b) 0.54 (0.34e0.86)
(c) 0.58 (0.30e1.12)
0.88 (0.84e0.92)
(a) 0.86 (0.79e0.94)
(b) 0.88 (0.78e1.00)
(c) 0.86 (0.72e1.03)
Age, sex, education,
smoking, number of 24-h
dietary records, height, and
family history of cancer.
For women also,
number of biological
children, menopausal status,
hormonal treatment of
menopause, and oral
contraception use
Xu, 2019
Canada
Alberta’s Tomorrow
Project (ATP) Study
Cohort
M/W (50.5 y)
2066/25 100
(11.7 y)
(a) 454
(b) 360
(c) 221
(d) 186
(e) 611
(f) 1209
Total cancer
(a) Breast
(b) Prostate
(c) Colorectal
(d) Lung
(e) Smoking related
(f) Obesity related
6 recommendations
(BW, PA, PF, AF, A, SU)
0e6 points
High (4e6) versus
Low (0e2)
0.87 (0.78e0.98)
(a) 0.86 (0.68e1.09)
(b) 0.99 (0.76e1.29)
(c) 0.67 (0.48e0.95)
(d) 0.84 (0.58e1.22)
(e) 0.79 (0.65e0.97)
(f) 0.86 (0.75e0.99)
Age, sex, marital status,
education, employment
status, annual household
income, smoking,
ﬁrst-degree family history
of cancer, history of chronic
disease (high blood pressure,
angina, high cholesterol
in blood, heart attack,
stroke), and hormone
replacement for women
Breast cancer
Hastert, 2013
USA
Vitamins and lifestyle
(VITAL) Study
Cohort
M/W (50e76 y)
899/30 797
(6.7 y)
Postmenopausal
breast cancer
(a) ER+
(b) ER
6 recommendations
(BW, PA, FPWG,
PF, AF, A)
0e6 points
High (5e6) versus
Low (0)
1-unit increase
0.40 (0.25e0.65)
0.89 (0.84e0.95)
(a) 0.90 (0.85e0.96)
(b) 0.84 (0.72e0.99)
Age, education, race,
mammography, family
history, age at menarche,
age at ﬁrst birth, age at
menopause, years of hormone
therapy, energy intake
Catsburg, 2014
Canada
Canadian National
Breast Screening Study
Cohort
W (40e59 y)
1970/47 130
(16.6 y)
Breast cancer 7 recommendations
(BW, PA, FPWG, PF,
AF, A, S)
0e7 points
High (6e7) versus
Low (0e1)
1-unit increase
0.79 (0.57e1.10)
0.95 (0.91e0.98)
Age, reproductive factors,
family history, benign breast
disease, menopausal
status, study center
Fanidi, 2015
Mexico
Cancer de Mama
(CAMA) Study
980/1074
(a) 405
(b) 575
Breast cancer
(a) Premenopausal
(b) Postmenopausal
7 recommendations
(BW, PA, FPWG, PF,
AF, A, BF)
Q4 versus Q1 (0e3.25) 1.04 (0.78e1.41)
(a) 1.17 (0.75e1.82)
(b) 0.97 (0.64e1.46)
Age, region, health care
institution, age ﬁrst
pregnancy, number
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Table 2. Continued
Author, year
Country
Study name
Study design
Sex, age (years)
Cases/total N
(years follow-up)
or cases/controls
Cases of secondary
outcomes
Outcome
Secondary
outcomes
Components of the
WCRF/AICR score
Score range
Comparison RR (95% CI)
RR (95% CI) for
secondary outcomes
Adjustment factors
Case control
W (35e69 y)
0e7 points pregnancies, socioeconomic
status, age menarche,
hormone therapy,
family history
Castelló, 2015
Spain
EpiGEICAM
Case control
W (22e71 y)
973/973
(a) 513
(b) 460
(c) 653
(d) 199
(e) 119
Breast cancer
(a) Premenopausal
(b) Postmenopausal
(c) ER+/PR+ & HER2
(d) HER2+
(e) ER & PR
& HER2
9 recommendations
(BW, PA, FPWG, PF,
AF, A, S, SU, BF)
0e9 points
Low (0e<3) versus
High (6e9)
1-unit decrease
2.98 (1.59e5.59)
(a) 2.66 (1.23e5.76)
(b) 3.60 (1.24e10.47)
(c) 3.60 (1.84e7.05)
(d) 4.23 (1.66e10.78)
(e) 2.32 (1.20e4.46)
1.22 (1.11e1.34)
(a) 1.20 (1.06e1.36)
(b) 1.24 (1.10e1.41)
(c) 1.26 (1.14e1.40)
(d) 1.20 (1.03e1.40)
(e) 1.20 (0.99e1.46)
Age, hospital, energy
intake, smoking, age
at ﬁrst delivery,
education, history of
breast problems, family
history of breast cancer,
and menopausal status
Nomura, 2016
USA
Iowa Women’s
Health Study (IWHS)
Cohort
W (61.7 y)
3189/36 626
(1986e2010)
Postmenopausal
breast cancer
7 recommendations
(BW, PA, SD,
PF, AF, A, S)
0e8 points
High (6e8) versus
Low (0e3.5)
0.5-unit increase
0.76 (0.67e0.87)
0.94 (0.90e0.97)
Age, smoking, education,
hormone replacement therapy,
family history of breast
cancer, menarche age,
menopause age, and parity
Harris, 2016
Sweden
Swedish Mammography
Cohort (SMC)
Cohort
W (61.4 y)
1388/31 514
(15 y)
(a) 746
(b) 118
Postmenopausal
breast cancer
(a) ER+/PR+
(b) ER/ER
7 recommendations
(BW, PA, FPWG,
PF, AF, A, SU)
0e7 points
High (6e7) versus
Low (0e2)
1-unit increase
0.49 (0.35e0.70)
(a) 0.44 (0.27e0.70)
(b) 0.90 (0.33e2.42)
0.89 (0.83e0.95)
(a) 0.86 (0.79e0.94)
(b) 1.01 (0.79e1.29)
Age, height, education, oral
contraceptive use, hormone
replacement therapy use,
age at menarche, age at
menopause, family history
of breast cancer, history
of benign breast
disease, smoking
Nomura, 2016
USA
Black Women’s Health
Study (BWHS)
Cohort
W (21e69 y)
1567/42 792
(13.86 y)
(a) 678
(b) 826
(c) 686
(d) 196
(e) 399
Breast cancer
(a) Premenopausal
(b) Postmenopausal
(c) ER+ and PR+
(d) ER+ or PR+
(e) ER and PR
7 recommendations
(BW, PA, SD, PF,
AF, A, S)
‘time-varying score’
0e7 points
High (>4e7) versus
Low (<3)
0.5-unit increase
0.84 (0.65e1.08)
(a) 0.67 (0.44e1.03)
(b) 1.00 (0.72e1.40)
(c) 0.97 (0.67e1.42)
(d) 1.33 (0.70e2.53)
(e) 0.32 (0.14e0.74)
0.89 (0.84e0.96)
(a) 0.90 (0.82e1.00)
(b) 0.90 (0.81e0.99)
(c) 0.93 (0.83e1.03)
(d) 1.02 (0.84e1.24)
(e) 0.85 (0.74e0.98)
Age, region, energy intake,
smoking, family history of
breast cancer, education,
menopausal status, oral
contraceptive use, parity,
menopausal hormone use
Colorectal cancer
Nomura, 2016
USA
Black Women’s
Health Study (BWHS)
Cohort
W (21e69 y)
328/42 792
(15.1 y)
(a) 259
Colorectal cancer
(a) Colon
7 recommendations
(BW, PA, SD, PF,
AF, A, S)
High (>4e7) versus
Low (<3)
0.5-units increase
0.51 (0.23e1.10)
(a) 0.54 (0.23e1.26)
0.98 (0.84e1.15)
(a) 1.00 (0.83e1.19)
Age, region, energy intake,
smoking, family history of
colorectal cancer, education,
menopausal status, diabetes,
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Table 2. Continued
Author, year
Country
Study name
Study design
Sex, age (years)
Cases/total N
(years follow-up)
or cases/controls
Cases of secondary
outcomes
Outcome
Secondary
outcomes
Components of the
WCRF/AICR score
Score range
Comparison RR (95% CI)
RR (95% CI) for
secondary outcomes
Adjustment factors
‘time-varying score’
0e7 points
insulin usage, aspirin usage,
colonoscopy, sigmoidoscopy
Hastert, 2016
USA
VITAL Study
Cohort
M/W (50e76 y)
546/66 920
(7.6 y)
Colorectal cancer 6 recommendations
(BW, PA, FPWG,
PF, AF, A)
0e6 points
High (4e6) versus
Low (0)
1-unit increase
0.42 (0.26e0.66)
0.87 (0.80e0.95)
Age, sex, education, race,
colonoscopy/sigmoidoscopy
in 10 years before baseline,
family history of colorectal
cancer, NSAID use, other
cancer diagnosis,
energy intake
Turati, 2017
Italy
Two case control
M/W (19e74; 31e80 y)
2246/4463
(a) 1420
(b) 818
Colorectal cancer
(a) Colon
(b) Rectum
7 recommendations
(BW, PA, FPWG, FP,
AF, A, S)
0e7 points
High (5e7) versus
Low (<3.5)
1-unit increase
0.67 (0.56e0.80)
(a) 0.67 (0.54e0.82)
(b) 0.67 (0.52e0.87)
0.83 (0.78e0.89)
Age, sex, study, center,
education, family history
of colorectal cancer, and
non-alcoholic energy intake
Jones, 2018
UK
UK Women’s
Cohort Study
Cohort
W (52.3 y)
444/30 963
(17.4 y)
(a) 322
(b) 146
Colorectal cancer
(a) Colon
(b) Rectum
8 recommendations
(BW, PA, FPWG, PF,
AF, A, S, BF)
0e8 points
High (>5e8) versus
Low (0e3)
1-unit increase
0.73 (0$48e1$10)
(a) 0.72 (0.44e1.19)
(b) 0.61 (0.29e1.26)
0.92 (0.82e1.03)
(a) 0.93 (0.82e1.07)
(b) 0.88 (0.72e1.08)
Age, smoking, socioeconomic
status and family history
of colorectal cancer
El Kinany, 2019
Morocco
Case control
M/W (56 y)
1453/1453
(a) 729
(b) 724
Colorectal cancer
(a) Colon
(b) Rectum
6 recommendations
(BW, PA, FPWG,
PF, AF, A)
0e6 points
T3 (>4e6) versus
T1 (<3.5)
0.58 (0.51e0.66)
(a) 0.63 (0.53e0.76)
(b) 0.52 (0.43e0.63)
Age, area of residence,
education, monthly income,
family history of colorectal
cancer, smoking, energy intake
Head and neck
Bravi, 2017
Italy
Two case control
M/W (19e82; 21e80 y)
1495/3458
(a) 871
(b) 624
Head and neck cancer
(a) Oral cavity and
pharynx
(b) Larynx
7 recommendations
(BW, PA, FPWG,
FP, FA, A, S)
0e7 points
High (5e7) versus
Low (<3)
1-unit increase
0.27 (0.20e0.37)
(a) 0.32 (0.22e0.49)
(b) 0.24 (0.15e0.38)
0.60 (0.55e0.66)
(a) 0.61 (0.54e0.69)
(b) 0.59 (0.51e0.68)
Age, sex, center, year of
interview, education, smoking,
body mass index,
non-alcohol energy intake
Prostate cancer
Er, 2014
UK
PSA-tested cohort
ProtecT trial
Case control
M (50e69 y)
1806/12 005
(a) 1612
(b) 184
(c) 1204
(d) 596
PSA-detected
prostate cancer
(a) Localized
(b) Locally advanced
(c) Low grade
(d) High grade
6 recommendations
(BW, PA, FPWG,
PF, AF, A)
0e6 points
High (4e6) versus
Low (0e2)
1-unit increase
1.01 (0.85e1.19)
(a) 0.99 (0.83e1.19)
(b) 1.16 (0.72e1.84)
(c) 1.00 (0.81e1.24)
(d) 1.00 (0.76e1.31)
0.99 (0.94e1.05)
(a) 0.99 (0.93e1.05)
(b) 1.00 (0.85e1.18)
(c) 1.00 (0.93e1.07)
(d) 0.97 (0.89e1.07)
Age, center, family history
of prostate cancer, smoking,
total energy intake
Pancreatic cancer
Lucas, 2016
Italy
Case control
M/F (63 y)
299/596 Pancreatic cancer 7 recommendations
(BW, PA, FPWG,
PF, AF, A, S)
0e7 points
High (5e7) versus
Low (<3.5)
1-unit increase
0.41 (0.24e0.68)
0.72 (0.60e0.87)
Sex, study center, year
of interview, age,
education, smoking,
and history of diabetes
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Table 2. Continued
Author, year
Country
Study name
Study design
Sex, age (years)
Cases/total N
(years follow-up)
or cases/controls
Cases of secondary
outcomes
Outcome
Secondary
outcomes
Components of the
WCRF/AICR score
Score range
Comparison RR (95% CI)
RR (95% CI) for
secondary outcomes
Adjustment factors
B. Mortality
General population
Vergnaud, 2013
Denmark, France,
Germany, Greece,
Italy, the Netherlands,
Spain, Sweden, UK
EPIC
Cohort
M/W (25e70 y)
23 828/378 864
(12.8 y)
(a) 9388
(b) 5229
(c) 1004
(d) 4228
All-cause mortality
Death due to:
(a) Cancer
(b) Circulatory disease
(c) Respiratory disease
(d) Other causes
7 recommendations
(BW, PA, FPWG, PF,
AF, A, BF)
0e7 points women
0e6 points men
High (5e6 M/6e7 W)
versus Low (0e2
M/0e3 W)
1-unit increase
0.66 (0.60e0.73)
(a) 0.80 (0.69e0.93)
(b) 0.56 (0.46e0.69)
(c) 0.50 (0.31e0.80)
(d) 0.55 (0.43e0.70)
0.87 (0.86;0.88)
(a) 0.91 (0.89e0.93)
(b) 0.83 (0.81e0.86)
(c) 0.79 (0.74e0.85)
(d) 0.83 (0.80e0.86)
Sex, age, center, education,
smoking, menopausal status
Hastert, 2014
USA
VITAL Study
Cohort
M/F (50e76 y)
1595/57 841
(7.7 y)
Cancer-speciﬁc
mortality
6 recommendations
(BW, PA, FPWG,
PF, AF, A)
0e6 points
High (5e6) versus
Low (0)
1-unit increase
0.39 (0.24e0.62)
0.89 (0.84e0.95)
Age, sex, education,
race/ethnicity, screenings,
NSAI/aspirin use, smoking,
energy intake, reproductive
factors
Lohse, 2016
Switzerland
MONItoring the trends
and determinants in
Cardiovascular disease
(MONICA) & National
Research Program
1A (NRP1A)
Cohort
M/W (25e74 y)
2715/16 722
(21.7 y)
(a) 992
(b) 187
(c) 57
(d) 21
(e) 79
(f) 40
(g) 55
(h) 39
(i) 115
(j) 71
(k) 73
(l) 60
(m) 828
All-cause mortality
(a) Total cancer death
(b) Lung
(c) Upper aerodigestive
tract
(d) Stomach
(e) Colorectal
(f) Liver
(g) Pancreatic
(h) Urinary tract
(i) Blood
(j) Prostate
(k) Breast
(l) Female genital tract
(m) Cardiovascular
disease death
7 recommendations,
9 sub-recommendations
(BW, PA, SB, ED, FV,
G, AF, A, S)
0e9 points
High (5e9) versus
Low (0e3.5)
1-unit increase
0.82 (0.75e0.89)
(a) 0.74 (0.64e0.86)
(b) 0.72 (0.51e0.99)
(c) 0.49 (0.26e0.92)
(d) 0.34 (0.14;0.83)
(e) 0.84 (.050e1.42)
(f) 1.07 (0.54e2.11)
(g) 0.65 (0.35e1.20)
(h) 0.63 (0.31e1.28)
(i) 1.04 (0.65e1.67)
(j) 0.48 (0.28e0.82)
(k) 0.76 (0.45e1.30)
(l) 0.66 (0.35e1.25)
(m) 0.96 (0.82e1.13)
0.93 (0.90e0.95)
(a) 0.90 (0.86e0.94)
(b) 0.90 (0.81e1.00)
(c) 0.82 (0.67e1.00)
(d) 0.71 (0.54e0.95)
(e) 0.86 (0.73e1.02)
(f) 0.98 (0.77e1.24)
(g) 0.88 (0.72e1.07)
(h) 0.99 (0.78e1.26)
(i) 0.98 (0.85e1.13)
(j) 0.79 (0.66e0.95)
(k) 0.91 (0.77e1.08)
(l) 0.90 (0.73e1.09)
(m) 0.97 (0.92e1.02)
Age, sex, education, marital
status, study, language
region, nationality, smoking
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Table 2. Continued
Author, year
Country
Study name
Study design
Sex, age (years)
Cases/total N
(years follow-up)
or cases/controls
Cases of secondary
outcomes
Outcome
Secondary
outcomes
Components of the
WCRF/AICR score
Score range
Comparison RR (95% CI)
RR (95% CI) for
secondary outcomes
Adjustment factors
Cancer survivors
Inoue-Choi, 2013
USA
Iowa Women’s
Health Study
Cohort
W (78.9 y)
461/2017
(5.4 y)
(a) 184
(b) 145
All-cause mortality
among older female
cancer survivors
(a) Cancer-speciﬁc
mortality
(b) Cardiovascular
disease-speciﬁc
mortality
Note that it also
provided results
according to primary
cancer site, not
included here.
7 recommendations
(BW, PA, SD,
PF, AF, A, S)
0e7 points
Q4 (6e8) versus
Q1 (1.5e4)
0.67 (0.49e0.90)
(a) 0.63 (0.39e1.04)
(b) 0.92 (0.57e1.47)
Age, number of comorbid
conditions, perceived health,
smoking, cancer stage, type,
treatment, other cancer
diagnosis, person-years
since diagnosis
Romaguera, 2015
Denmark, France,
Germany, Greece,
Italy, the Netherlands,
Spain, Sweden, UK
EPIC
Cohort
M/W (25e70 y)
872/3292
(4.2 y)
1113
Colorectal
cancer-speciﬁc
mortality among
colorectal cancer
cases
Overall mortality
among colorectal
cancer cases
7 recommendations
(BW, PA, FPWG, PF,
AF, A, BF)
0e7 points women
0e6 points men
High (4e6 M/5e7 W)
versus Low (0e2
M/0e3 W)
1-unit increase
0.70 (0.56e0.89)
0.79 (0.65e0.98)
0.90 (0.83e0.97)
0.93 (0.87e0.99)
Age, country, sex, education,
smoking, year of colorectal
cancer diagnosis, tumor
stage, grade, and site
M, men; NSAID, nonsteroidal anti-inﬂammatory drug; Q, quantile; T, tertile; UADT, upper aerodigestive track; W, women.
Components of the 2007 WCRF/AICR score: A, alcohol; AF, animal foods; BW, body weight; FPWG, foods that promote weight gain; PA, physical activity; PF, plant foods; S, salt; SU, dietary supplements.
Sub-recommendations of the 2007 WCRF/AICR score: ED, energy-dense foods (excluding sweet drinks); F, ﬁber; FV, fruits and vegetables; G, grains; SB, sedentary behavior; SD, sweet drinks.
In Xu et al., 2019. Smoking-related cancers include bladder, colon, esophagus, kidney, larynx, liver, lung and bronchus, ovary (mucinous tumors), pancreas, rectum, stomach, and uterine cervical cancers. Obesity-related cancers include breast,
prostate, colon, rectum, endometrial, kidney, and ovarian cancers.
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Figure 1. Dose-response meta-analysis of studies examining the association between adherence to the WCRF/AICR recommendations and breast cancer risk by
study design.
The results from the study by Castelló et al.50 were inverted and those from the study by Nomura et al.44,45 were converted from 0.5- to 1-point increase. Dose-response
estimates were calculated from the categorical data for the study by Xu et al.,41 but not for the study by Fanidi et al.49 (not included here), which did not provide enough
data. The studies by Nomura et al.44 (IWHS), Hastert et al.,42 and Harris et al.46 only included postmenopausal women.
Annals of Oncology M. Solans et al.Association with mortality
In the general population. Three cohort studies evaluated
adherence to the 2007 WCRF/AICR recommendations andTable 3. Subgroup meta-analyses of studies examining adherence to the WCRF/
Dose-response meta-analysis (1-unit increase)
n Summary RR (95% CI) I2 (%)
Breast cancer
All studiesa,b 11 0.90 (0.87e0.93) 69.8
Study design
Prospective cohort 9 0.91 (0.88e0.94) 62.8
Case-control 2 0.84 (0.78e0.89) 0.0
Geographical location
North America 6 0.91 (0.86e0.95) 61.4
Europe 5 0.88 (0.83e0.94) 80.0
South America
Menopausal status
Premenopausal 4 0.89 (0.81e0.99) 38.6
Postmenopausal 7 0.86 (0.83e0.89) 12.3
Hormone receptor
HR positive 6 0.87 (0.83e0.91) 3.7
HR negative 6 0.84 (0.77e0.91) 0.0
Colorectal cancer
All studiesb 10 0.86 (0.82e0.89) 53.2
Study design
Prospective cohort 7 0.89 (0.86e0.91) 0.0
Case control 3 0.81 (0.76e0.88) 79.2
Geographical location
Europe 5 0.84 (0.78e0.90) 75.8
North America 4 0.89 (0.84e0.94) 0.0
North Africa 1 0.85 (0.82e0.89) e
Site
Colon 5 0.87 (0.80e0.94) 77.7
Rectal 4 0.84 (0.78e0.91) 70.7
n denotes the number of risk estimates and Ph the P for heterogeneity.
a The cohort study by Makarem et al. 2015 was not included in the categorical meta-anal
b The case-control study by Fanidi et al. 2015 could not be included in the dose-response me
response estimates).
362 https://doi.org/10.1016/j.annonc.2020.01.001mortality in the general population35e37 (Table 2,
Figure 4A). Dose-response meta-analyses revealed inverse
associations between adherence to the 2007 WCRF/AICRAICR score and breast and colorectal cancer risk
Highest versus lowest meta-analysis
Ph n Summary RR (95% CI) I2 (%) Ph
<0.001 11 0.74 (0.65e0.83) 67.6 <0.001
0.01 8 0.73 (0.64e0.83) 65.7 0.01
0.58 3 0.74 (0.46e1.09) 80.8 0.01
0.02 5 0.76 (0.64e0.89) 53.4 0.07
<0.001 5 0.65 (0.52e0.82) 78.6 <0.001
1 1.04 (0.77e1.40) e e
0.18 4 0.80 (0.55e1.17) 61.5 0.05
0.35 7 0.66 (0.53e0.83) 71.5 <0.001
0.39 5 0.70 (0.47e1.04) 75.4 <0.001
0.56 5 0.57 (0.40e0.80) 33.1 0.20
0.02 9 0.62 (0.56e0.70) 49.7 0.04
0.97 6 0.67 (0.57e0.78) 19.7 0.29
0.01 3 0.59 (0.53e0.66) 35.1 0.21
<0.001 5 0.65 (0.56e0.75) 55.5 0.06
0.87 3 0.55 (0.40e0.75) 22.5 0.28
e 1 0.58 (0.51e0.66) e e
<0.001 5 0.60 (0.54e0.67) 1.6 0.40
0.02 4 0.56 (0.49e0.64) 0.0 0.47
ysis of breast and colorectal cancers (it only provided dose-response estimates).
ta-analysis of breast cancer (not enough information was provided to compute dose-
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Figure 2. Dose-response meta-analysis of studies examining the association between adherence to the WCRF/AICR recommendations and colorectal cancer risk by
study design.
Dose-response estimates were calculated from the categorical data for the study by El Kinany et al.16 The results from Nomura et al.47 were converted from 0.5- to
1-point increase.
M. Solans et al. Annals of Oncologyscore and overall mortality (RR 0.90, 95% CI 0.84e0.96)
with a high heterogeneity between the two studies (I2
94.9%, P for heterogeneity <0.001, n ¼ 2) (data not
shown). Greater adherence to the score was also associated
with lower cancer-speciﬁc mortality (RR 0.91, 95% CI 0.89e
0.92, I2 0.0%, P for heterogeneity 0.86, n ¼ 3) while null
associations were reported for cardiovascular disease mor-
tality (RR 0.90, 95% CI 0.77e1.04, I2 96.2%, P for hetero-
geneity <0.001, n ¼ 2).
In cancer survivors. Two cohort studies assessed the impact
of following the 2007 WCRF/AICR recommendations (pre-
diagnostic concordance) on survival in cancer patients
(Table 2, Figure 4B). Inoue-Choi et al. found a lower all-
cause mortality among older female cancer survivors with
greater adherence to such recommendations (HRhighvslow
0.67, 95% CI 0.49e0.90) yet null results were reported for
cancer and cardiovascular speciﬁc mortality.38 Similarly,
Romaguera et al. reported a lower overall mortality
(HRhighvslow 0.79, 95% CI 0.65e0.98) and colorectal cancer
mortality (HRhighvslow 0.70, 95% CI 0.56e0.89) among
colorectal cancer survivors showing higher adherence to the
WCRF/AICR recommendations.39
Associations with other health outcomes and risk factors
A total of 13 cross-sectional studies evaluated the associa-
tion between adherence to the 2007 WCRF/AICR score and
other health outcomes both in cancer patients/survivors
and in the general population.
In the general population. Three studies analyzed the as-
sociation between adherence to the 2007 WCRF/AICR rec-
ommendations and markers of cancer risk. In a study of 107
patients undergoing upper gastrointestinal endoscopy for
gastroesophageal reﬂux (high-risk population), higherVolume 31 - Issue 3 - 2020adherence to the recommendations was inversely associ-
ated with Barrett’s esophagus onset (one of the main risk
factors of esophageal adenocarcinoma) and its evolution to
early esophageal adenocarcinoma.28 In another study of
3584 women attending breast cancer screening, higher
adherence to the recommendations was associated with
lower mammographic density, a predictor of breast cancer,
mostly in postmenopausal women and non-smokers.26 A
small study including 75 healthy participants showed that
higher adherence to the recommendations (plus a recom-
mendation regarding smoking status) was associated with
reduced expression of WNT-pathway-related markers of
bowel cancer risk.22 In addition, two studies on healthy
populations explored the molecular mechanisms underlying
the associations found. The largest study, involving 19 478
individuals, found that greater adherence to the 2007
WCRF/AICR recommendations was associated with healthier
proﬁle of plasma markers of inﬂammation (CRP, IL6, TNFaR2,
and adiponectin), hormonal response (estrone and estradiol),
and insulin response (C-peptide and TG/HDL), which was
mainly driven by energy balance recommendations.30
Another study in 275 premenopausal women found that
women with a higher adherence score show lower levels of
CRP and alpha-tocopherol but not F2-isoprostane.25
In cancer patients or survivors. Only one study assessed the
relationship between adherence to the recommendations
and cancer aggressiveness. In 2212 newly diagnosed cases
of prostate cancer, higher 2007 WCRF/AICR scores were
associated with lower odds of highly aggressive prostate
cancer [based on Gleason scores, serum prostate-speciﬁc
antigen (PSA) and TNM classiﬁcation stage of malignant
tumors].20 The rest of the studies addressed health status
and quality of life. Two of them, one in adult survivors of
childhood cancer24 and one in patients with breast cancerhttps://doi.org/10.1016/j.annonc.2020.01.001 363
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Figure 3. Dose-response cancer incidence umbrella review of cancers other than breast and colorectal cancer, summarized in Figures 1 and 2.
Dose-response estimates were calculated from the categorical data for the study by Xu et al.41
Annals of Oncology M. Solans et al.5 years after a cancer diagnosis,29 reported an association
between lower 2007 WCRF/AICR scores and metabolic
equivalent of task (MetS) exercise capacity risk or preva-
lence, respectively. Regarding ﬁndings on health-related
quality of life, the largest study, conducted on 2193
elderly female cancer survivors (average survival of 8.9
years), found that those who met a greater number of
recommendations had better health-related quality of life,
scoring higher in both the mental and physical components
of the SF-36.19 Two Dutch studies assessed quality of life in
colorectal cancer survivors. The largest study,23 including
1096 individuals (mean time since diagnosis 8.1 years),
found better global health status, better physical, role, and
social functional scales, and reduced fatigue in individuals
with higher scores. In the other study21 including 145 in-
dividuals (mean survival from diagnosis 5.7 years), greater
adherence to the recommendations was not associated
with an overall score of quality of life but with a better364 https://doi.org/10.1016/j.annonc.2020.01.001physical function and reduced fatigue. Finally, there were
two studies on patients recently diagnosed with breast
cancer, which resulted in discordant results. In one study of
1462 women diagnosed with early-stage breast cancer,
adherence to the recommendations was associated with
better global health status, physical and role functioning,
and lower levels of fatigue, nausea/vomiting, dyspnea, loss
of appetite, and diarrhea.31 By contrast, a small study of 160
Korean women not only found no associations with a better
global health-related quality of life but also reported more
serious arm symptoms in those patients with higher 2007
WCRF/AICR scores.27Study quality
In most studies, dietary and physical activity were typically
collected using self-reported data, which can lead to
exposure measurement error. Except for a fewVolume 31 - Issue 3 - 2020
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Figure 4. Dose-response mortality umbrella review of studies A) in the
general population, and B) in cancer survivors.
Dose-response results for the study by Inoue-Choi et al.38 were calculated from
categorical results. Note that the study population in the article by Romaguera
et al.39 were only colorectal cancer cases (and cancer-speciﬁc results only refer
to deaths due to colorectal cancer). The population identiﬁed by Inoue-Choi
et al.38 were women survivors of different types of cancer (the original
article also provides estimates according to the primary cancer site, not included
here).
M. Solans et al. Annals of Oncologystudies,21,23,27e29,37 dietary data was recorded mainly
through a validated food frequency questionnaire (FFQ).
FFQ validation methods generally relied on self-reported
measures (i.e. 24-h recall or dietary records) rather than
objective measures (i.e. nutrient biomarkers) and correla-
tions were examined for dietary factors that were not al-
ways components of the 2007 WCRF/AICR score. Fewer
studies reported the use of validated tools to assess phys-
ical activity4,19,21,23,24,30,31,33,35,36,38e42,44e49 and again,
were not always based on objective methods, such as
accelerometers. Regarding limitations of study design, case-
control studies reported stronger associations but signiﬁ-
cant associations were also observed in cohort studies,
which are less prone to recall and selection bias. In addition,
larger studies tended to report associations that were not
conﬁrmed in some small studies. Moreover, there were
three hospital-based case-control studies51,52,54 that were
particularly prone to selection bias. All the cohort studies
but one relied on a singular measure of exposure at base-
line to construct their scores and thus could not account for
any possible changes in dietary and lifestyle habits over
time; the exception was the study by Nomura et al.45,47 thatVolume 31 - Issue 3 - 2020analyzed a time-varying score using the Andersen-Gill
model. Finally, all of the studies adjusted for several con-
founding factors, although there were great differences in
the level of adjustment across studies (Table 2). Most of
them, however, adjusted at least for age, sex (when appli-
cable), education/socioeconomic status, and smoking.DISCUSSION
This study provides the most comprehensive and up-to-date
summary of evidence of the association between the 2007
WCRF/AICR recommendations and health outcomes. We
reported, per each point increment in the score, a 10% and
14% reduction of breast and colorectal risk estimates,
respectively, and, although based on fewer studies, a lower
overall (10%) and cancer-speciﬁc mortality (9%) in the
general population and better cancer survival. Several cross-
sectional studies have also reported a healthier plasma
marker proﬁle and lower cancer risk factors in the general
population and better health status and quality of life in
cancer patients/survivors.
Our results are in line with a previous systematic review
of cohort studies55 that examined the associations between
adherence to the 2007 WCRF/AICR and American Cancer
Society cancer prevention guidelines and cancer risk and
mortality. In our study, we further expanded the analysis to
include case-control and cross-sectional studies and added
newly published data, which allowed us to carry out site-
speciﬁc meta-analyses. In the meta-analyses of breast and
colorectal cancer, studies consistently observed inverse as-
sociations for both cancer types and although there was
evidence of heterogeneity of study results, this was due to
the difference in magnitude instead of the direction of the
association. Fewer studies evaluated such associations with
other cancer types. No associations were reported for
prostate and pancreatic cancers, while results from two
studies suggest an inverse link for lung cancer. Regarding
lung cancer results, smoking was included as an adjusting
covariate in both studies, but with different levels of
speciﬁcity. Xu et al.41 only considered tobacco exposure
while Romaguera et al.4 used a far more complete variable
detailing both smoking status and intensity. The association
with other cancer sites (e.g. endometrial, head and neck,
liver, kidney, esophageal, ovarian, or stomach) has been
investigated only in the EPIC study and thus merits further
research. Mortality data is scarcer and mainly arises from
the EPIC study, but results also point to an inverse associ-
ation between adherence to the 2007 WCRF/AICR recom-
mendations and overall mortality and cancer-speciﬁc
mortality in healthy populations as well as a higher survival
in those cancer patients following such recommendations.
Moreover, several cross-sectional studies reported associa-
tions between higher adherence to the 2007 WCRF/AICR
score and healthier plasma marker proﬁle and lower cancer
risk factors as well as reduced cancer aggression and better
health status and quality of life in cancer patients/survivors.
The publication of the WCRF/AICR Second Expert Report
demonstrated the importance of a structured process ofhttps://doi.org/10.1016/j.annonc.2020.01.001 365
Annals of Oncology M. Solans et al.collection and review of available data and set the bench-
mark for evidence-based guidance.3 It also provided evi-
dence for the importance of shifting toward a holistic
approach in cancer prevention through a set of recom-
mendations underpinning a comprehensive package of
healthy lifestyle habits. Its operationalization into the 2007
WCRF/AICR score, however, entails several limitations. First,
integrating several lifestyle factors into a single index re-
duces the level of variability across individuals although it
captures a general pattern. Secondly, the score is not
weighted, assuming that all components are equally and
additively related to health. Nevertheless, some recom-
mendations might be more relevant to a speciﬁc outcome,
such as breastfeeding in breast cancer, meat intake in
colorectal cancer, or body mass index in obesity-related
cancers. Thirdly, some components are correlated (i.e.
physical activity, body fatness, and foods that promote
weight gain). Finally, the score does not address other major
risk factors for cancer such as smoking or sun exposure.
Similarly, other factors, such as abdominal adiposity mea-
surements (instead of body weight), may be better pre-
dictors of some cancer types.56,57
In 2018, the recommendations were updated, based on a
comprehensive literature review of the past 10 years.5
While remaining somewhat consistent with the previous
report, there was a signiﬁcant shift in emphasis to an in-
tegrated pattern of behaviors relating to diet, body fatness,
and physical activity. There were also some speciﬁc key
changes: (i) high-calorie foods and sugar-sweetened drinks
are now separated into two independent recommendations
(limit fast foods and limit sugar-sweetened drinks), (ii) there
is no longer a recommendation for salt, and (iii) there is no
level of alcohol consumption below which there is no in-
crease in the risk of at least some cancers. Bearing in mind
the inherent limitations of comparing the previous scoring
approaches when operationalizing the 2007 cancer pre-
vention recommendations, an international collaboration
involving the US National Cancer Institute, members of
WCRF/AICR with advice from the CUP panel, and other in-
ternational researchers, has recently developed a standard
scoring system of the updated recommendations. Up-
coming studies using this new scoring system will help to
draw ﬁrmer conclusions regarding the associations found as
well as grow evidence in less explored (e.g. lung cancer) or
unexplored cancer sites (e.g. hematological malignancies)
and other relevant health outcomes (e.g. mortality, cancer
survival or risk of other non-communicable diseases).
The strengths of our study include the generally high
quality of publications included, the large number of end-
points examined, and the robustness of results from
numerous subgroups and sensitivity analyses. Nevertheless,
our results have some limitations. First, there is high het-
erogeneity in the score’s operationalization across different
studies, which hampers the direct comparability of the
ﬁndings. Although we took into account the different
ranges of the 2007 WCRF/AICR scores in the dose-response
analysis, studies would have also differed by how accurately
they measured anthropometric measures, dietary intake,366 https://doi.org/10.1016/j.annonc.2020.01.001and physical activity. While some degree of measurement
error is inevitable, efforts should be made to feasibly
address such limitations in upcoming observational studies,
as recently recommended.58 We excluded studies focusing
only on dietary components as we were interested in
studies with scores reﬂecting an overall lifestyle pattern. For
some outcomes, the number of studies was too small to
allow full exploration of heterogeneity or even perform
meta-analyses. We included case-control studies, which
might have been affected by recall bias (indeed, they ten-
ded to observe stronger associations), and potential selec-
tion bias. Regarding cohort studies, they may be affected by
the healthy cohort effect; therefore, the preventable frac-
tion in the general population is likely to be higher than the
one reported here. Although we summarized the results of
models with the highest level of adjustment, residual con-
founding cannot be ruled out. Finally, evidence of small-
study bias or publication bias in some of the analyses
suggests that the strength of the associations may have
been slightly overestimated in a few cases but this is un-
likely to substantially alter the overall ﬁndings of the study.
In conclusion, this systematic review and meta-analysis
provide evidence that adhering to the 2007 WCRF/AICR
cancer prevention recommendations is associated with a
lower risk of breast and colorectal cancer incidence and
mortality. Overall, primary prevention of cancer should
emphasize the modiﬁcation of multiple diet and lifestyle
factors. Upcoming studies examining the recently updated
WCRF/AICR cancer prevention recommendations will
further clarify these associations.
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